Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Non Operating Income (2020 - 2025)

Tango Therapeutics has reported Non Operating Income over the past 6 years, most recently at $1.4 million for Q4 2025.

  • Quarterly results put Non Operating Income at $1.4 million for Q4 2025, down 6.5% from a year ago — trailing twelve months through Dec 2025 was $5.3 million (down 30.26% YoY), and the annual figure for FY2025 was $4.1 million, down 46.54%.
  • Non Operating Income for Q4 2025 was $1.4 million at Tango Therapeutics, up from $705000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for TNGX hit a ceiling of $3.4 million in Q3 2023 and a floor of -$380000.0 in Q4 2021.
  • Median Non Operating Income over the past 5 years was $1.3 million (2023), compared with a mean of $1.2 million.
  • Biggest five-year swings in Non Operating Income: tumbled 445.45% in 2021 and later skyrocketed 5102.0% in 2023.
  • Tango Therapeutics' Non Operating Income stood at -$380000.0 in 2021, then soared by 510.0% to $1.6 million in 2022, then skyrocketed by 32.28% to $2.1 million in 2023, then decreased by 28.38% to $1.5 million in 2024, then dropped by 6.5% to $1.4 million in 2025.
  • The last three reported values for Non Operating Income were $1.4 million (Q4 2025), $705000.0 (Q3 2025), and $2.1 million (Q2 2025) per Business Quant data.